Aspergillus infections in the critically ill

Proceedings of the American Thoracic Society

Volumn 7, Issue 3, 2010, Pages 204-209

  Dutkiewicz, Radek ^a   Hage, Chadi A ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Aspergillus; Chronic obstructive pulmonary disease; Corticosteroids; Galactomannan; Intensive care unit

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

CRITICALLY ILL PATIENT; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; INTENSIVE CARE; INVASIVE ASPERGILLOSIS; LIVER TOXICITY; QT PROLONGATION; REVIEW; ARTICLE; ASPERGILLOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CRITICAL ILLNESS; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; NEUTROPENIA; RISK FACTOR;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; COMORBIDITY; CRITICAL ILLNESS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; INTENSIVE CARE UNITS; LIVER CIRRHOSIS; NEUTROPENIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 77955478959     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.200906-050AL     Document Type: Review

References (54)

1. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996;100: 171-178. (Pubitemid 26062511)
2. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000;26:S124-S128. (Pubitemid 30184503)
3. Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH. Immunoparalysis as a cause for invasive aspergillosis? Intensive Care Med 2003;29:2068-2071.
4. Segal BH. Aspergillosis. N Engl J Med 2009;360:1870-1884.
5. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32. (Pubitemid 26289847)
6. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007;45:205-216. (Pubitemid 47044802)
7. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, Morrison VA, Pappas P, Hiemenz JW, Stevens DA. The impact of culture isolation of aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001;33:1824-1833. (Pubitemid 33105120)
8. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006;10:R31.
9. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004;170:621-625. (Pubitemid 39202203)
10. Dimopoulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincent JL. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother 2003;15:71-75. (Pubitemid 36349895)
11. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, Iruretagoyena JR, Barcenilla F. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005;9:R191-R199.
12. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of icu stay and ventilator dependence. J Hosp Infect 2004;56:269-276. (Pubitemid 38444078)
13. Khasawneh F, Mohamad T, Moughrabieh MK, Lai Z, Ager J, Soubani AO. Isolation of aspergillus in critically ill patients: a potential marker of poor outcome. J Crit Care 2006;21:322-327. (Pubitemid 44908866)
14. Leav BA, Fanburg B, Hadley S. Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone. N Engl J Med 2000; 343:586. (Pubitemid 30650763)
15. Anaissie EJ, Stratton SL, Dignani MC, Summerbell RC, Rex JH, Monson TP, Spencer T, Kasai M, Francesconi A, Walsh TJ. Pathogenic aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002;34:780-789. (Pubitemid 34194848)
16. Pittet D, Huguenin T, Dharan S, Sztajzel-Boissard J, Ducel G, Thorens JB, Auckenthaler R, Chevrolet JC. Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:541-544. (Pubitemid 26271333)
17. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006;91:986-989.
18. Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001;7:54-61.
19. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-379. (Pubitemid 46147619)
20. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-366. (Pubitemid 32173620)
21. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007;30: 782-800. (Pubitemid 351194841)
22. Chow L, Brown NE, Kunimoto D. An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis. Clin Infect Dis 2002;35:e106-e110.
23. Barouky R, Badet M, Denis MS, Soubirou JL, Philit F, Guerin C. Inhaled corticosteroids in chronic obstructive pulmonary disease and disseminated aspergillosis. Eur J Intern Med 2003;14:380-382. (Pubitemid 40090264)
24. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008;177:27-34.
25. Denning DW. Commentary: unusual manifestations of aspergillosis. Thorax 1995;50:812-813.
26. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP III. Spectrum of aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001;119:169-175. (Pubitemid 32150563)
27. Tasci S, Glasmacher A, Lentini S, Tschubel K, Ewig S, Molitor E, Sauerbruch T, Luderitz B, Rabe C. Pseudomembranous and obstructive Aspergillus tracheobronchitis - optimal diagnostic strategy and outcome. Mycoses 2006;49:37-42.
28. Tait RC, O'Driscoll BR, Denning DW. Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. Thorax 1993;48:1285-1287. (Pubitemid 24009404)
29. Bulpa PA, Dive AM, Garrino MG, Delos MA, Gonzalez MR, Evrard PA, Glupczynski Y, Installe EJ. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 2001;27:59-67.
30. Miller WT. Aspergillosis: a disease with many faces. Semin Roentgenol 1996;31:52-66. (Pubitemid 26020298)
31. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813-1821.
32. Hachem R, Sumoza D, Hanna H, Girgawy E, Munsell M, Raad I. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised? Cancer 2006;106:1581-1586.
33. Levy H, Horak DA, Tegtmeier BR, Yokota SB, Forman SJ. The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis. Respir Med 1992;86:243-248.
34. Vandewoude KH, Vogelaers D. Medical imaging and timely diagnosis of invasive pulmonary aspergillosis. Clin Infect Dis 2007;44:380-381. (Pubitemid 46147620)
35. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42: 1417-1427.
36. Maertens JA, Klont R, Masson C, Theunissen K, Meersseman W, Lagrou K, Heinen C, Crepin B, Van Eldere J, Tabouret M, et al. Optimization of the cutoff value for the aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007;44:1329-1336. (Pubitemid 46729195)
37. Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis 2008;27:245-251.
38. Hage CA, Reynolds JM, Durkin M, Wheat LJ, Knox KS. Plasmalyte as a cause of false-positive results for aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol 2007;45:676-677.
39. Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003;349:2366-2367. (Pubitemid 37509754)
40. Surmont I, Stockman W. Gluconate-containing intravenous solutions: another cause of false-positive galactomannan assay reactivity. J Clin Microbiol 2007;45:1373. (Pubitemid 46626522)
41. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-1769. (Pubitemid 40799945)
42. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, et al. Multicenter clinical evaluation of the (1/3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654-659. (Pubitemid 41170353)
43. Egan L, Connolly P, Wheat LJ, Fuller D, Dais TE, Knox KS, Hage CA. Histoplasmosis as a cause for a positive fungitell (1 / 3)-beta-Dglucan test. Med Mycol 2008;46:93-95. (Pubitemid 351298247)
44. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003;10: 882-885. (Pubitemid 37129504)
45. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415. (Pubitemid 34851833)
46. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360. (Pubitemid 351265310)
47. Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 2007;33:1694-1703. (Pubitemid 47476659)
48. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-1572.
49. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211. (Pubitemid 351269158)
50. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-222. (Pubitemid 38223535)
51. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-220. (Pubitemid 40188942)
52. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42:1429-1438.
53. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, et al. Posaconazole or fluconazole for prophylaxis in severe graftversus- host disease. N Engl J Med 2007;356:335-347. (Pubitemid 46148776)
54. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-1734. (Pubitemid 43839438)